3种临时栓塞剂在通过导管动脉栓塞治疗退行性,炎症性和过度使用关节疾病中的比较安全性
Tijmen A van Zadelhoff1, Takatoshi Kubo2, Masahiko Shibuya3
1Department of Radiology and Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
Journal of vascular and interventional radiology : JVIR
|March 3, 2025
概括
三种栓塞性材料,即伊米 (IPM) /基 (CS),快溶性凝海绵颗粒 (QS-GSPs) 和可再吸收微球 (RMs),在关节疾病的横管动脉栓塞 (TAE) 中显示出安全有效的疼痛缓解.
科学领域:
- 干预性放射学 干预性放射学
- 整形外科 整形外科 整形外科
- 生物材料科学 生物材料科学
背景情况:
- 通过导管动脉栓塞 (TAE) 是各种关节疾病的有效治疗方法.
- 快速生物降解的栓塞性材料的开发对于提高TAE的安全性和有效性至关重要.
- 评估新型栓塞剂对于管理耐火性关节疼痛至关重要.
研究的目的:
- 评估三种不同的栓塞性材料所提供的安全性和疼痛缓解:伊米 (IPM) /基拉沙丁 (CS),快溶性凝海绵颗粒 (QS-GSPs) 和可再吸收微球 (RMs).
- 为了比较这些材料的结果在患者接受TAE退行性,炎症和过度使用的关节条件.
主要方法:
- 一项回顾性研究包括了431名患者 (527个关节) 在2020年3月至2023年5月期间接受了TAE治疗.
- 患者接受了IPM/CS,QS-GSP或RM,不良事件在手术后立即监测.
- 在TAE后1,3个月和6个月使用数值评分表 (NRS) 评估疼痛减轻.
主要成果:
- 在所有三种栓塞性材料中都没有报告严重不良事件.
- 在7.1% (IPM/CS),22.1% (QS-GSPs) 和5.8% (RMs) 的患者中,持续超过7天的增强后栓塞疼痛发生,主要发生在肘部.
- 在所有测试材料 (P < .0001) 的1,3个月和6个月观察到显著的疼痛减轻 (NRS得分改善).
结论:
- 伊米 (IPM) /基拉斯 (CS),快溶性凝海绵颗粒 (QS-GSPs) 和可再吸收微球 (RMs) 具有良好的安全性.
- 这些栓塞剂有效地缓解了TAE治疗的退行性,炎症性和过度使用关节疾病患者的疼痛.
- 栓塞材料的选择可能会影响过渡性术后疼痛的发生率.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
590
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
590
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
454
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
454


